Effect estimate: RR 0.82 (95% CI 0.59-1.14)
p-value: p=0.16
The 2018 ESC/EACTS guidelines provide comprehensive evidence-based recommendations for myocardial revascularization across various clinical scenarios.
No support for FDG-PET-guided revascularization in severe LV dysfunction; challenges viability imaging and leaves open refined selection criteria.
International audience
No takes yet. Share an insight, caveat, or question.
Neumann et al. (2020) studied Malattia coronarica (CAD). Rivascolarizzazione miocardica was evaluated on Morte cardiaca, infarto miocardico o riospedalizzazione per cause cardiache ad 1 anno (RR 0.82, 95% CI 0.59-1.14, p=0.16). Pazienti con disfunzione ventricolare sinistra severa non hanno mostrato miglioramenti significativi in termini di morte cardiaca, infarto miocardico o riospedalizzazione dopo rivascolarizzazione basata su FDG-PET, con un RR di 0.82.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: